EDITORIAL: No debate needed on drug prices - Insurance News | InsuranceNewsNet

InsuranceNewsNet — Your Industry. One Source.™

Sign in
  • Subscribe
  • About
  • Advertise
  • Contact
Home Now reading Newswires
Topics
    • Advisor News
    • Annuity Index
    • Annuity News
    • Companies
    • Earnings
    • Fiduciary
    • From the Field: Expert Insights
    • Health/Employee Benefits
    • Insurance & Financial Fraud
    • INN Magazine
    • Insiders Only
    • Life Insurance News
    • Newswires
    • Property and Casualty
    • Regulation News
    • Sponsored Articles
    • Washington Wire
    • Videos
    • ———
    • About
    • Meet our Editorial Staff
    • Advertise
    • Contact
    • Newsletters
  • Exclusives
  • NewsWires
  • Magazine
  • Newsletters
Sign in or register to be an INNsider.
  • AdvisorNews
  • Annuity News
  • Companies
  • Earnings
  • Fiduciary
  • Health/Employee Benefits
  • Insurance & Financial Fraud
  • INN Exclusives
  • INN Magazine
  • Insurtech
  • Life Insurance News
  • Newswires
  • Property and Casualty
  • Regulation News
  • Sponsored Articles
  • Video
  • Washington Wire
  • Life Insurance
  • Annuities
  • Advisor
  • Health/Benefits
  • Property & Casualty
  • Insurtech
  • About
  • Advertise
  • Contact
  • Editorial Staff

Get Social

  • Facebook
  • X
  • LinkedIn
Newswires
Newswires RSS Get our newsletter
Order Prints
February 23, 2017 Newswires
Share
Share
Post
Email

EDITORIAL: No debate needed on drug prices

Mail Tribune (Medford, OR)

Feb. 22--There is plenty of distance between Democrats and Republicans over health coverage -- Republicans want to dismantle the Affordable Care Act, Democrats want to keep it, and those in both parties who want to fix it can't begin to agree on how. But if there is one element of health care that has seemingly everyone on the same page, it's the soaring prices of prescription drugs.

Even President Donald Trump says price-gouging pharmaceutical companies are "getting away with murder." So why can't we fix that problem, and fight about the rest later?

The numbers are staggering: a more than 5,000 percent price increase for one medicine to treat parasitic infection, 2,000 percent for a drug to combat drug-resistant tuberculosis, 1,900 percent for a remedy for kidney and bladder stones.

These are not cases of companies investing millions to research and develop new drugs. The companies in question spent exactly zero on R&D.

Those price jumps came after the drugs were purchased from the companies that developed them by other companies, which then jacked up the price to recoup their investment and make enormous profits.

A bipartisan report by the U.S. Senate Special Committee on Aging called this the "patient as hostage" business model.

There is no question that developing new drugs is very expensive -- a function of the government's insistence on safety before releasing new drugs to the market. But when the companies that go to that expense are then bought out by other companies that boost the price even higher, it's the patients who lose -- and the insurance industry is forced to raise premiums and limit the patients who can receive the drugs to those who are sickest.

Patients and their families are willing to spend everything they own and more to obtain life-saving treatment. The drug companies know this, and price their products accordingly.

Solutions don't break down along party lines -- Democrats and Republicans were on both sides of a failed proposal to allow imports from Canada, where drugs are cheaper.

One obvious step is to allow Medicare -- the only single-payer health insurance system this country has -- to negotiate prices for prescriptions, something that is now prohibited under federal law.

Another fix must involve caps on prices of the most expensive drugs, with manufacturers required to reveal more of their costs if they want to justify continuing to charge super-premium prices.

Speeding up the approval process for generic drugs also will help.

While lawmakers dither over how to address this crisis, the losers are the American people. Congress must address the problem of prescription costs and do it now.

___

(c)2017 the Mail Tribune (Medford, Ore.)

Visit the Mail Tribune (Medford, Ore.) at www.mailtribune.com

Distributed by Tribune Content Agency, LLC.

Older

Ex-jail nurse asks for more time to prepare for trial in inmate death case

Newer

Democrats to rally for Affordable Care Act this Saturday in Aiken

Advisor News

  • NAIFA applauds final SECURE 2.0 regulations
  • What will Democrats in Congress do about healthcare and retirement?
  • Election results cloud retirement legislation outlook, experts say
  • Planning for the missing chapter
  • Semi-retirement: helping clients balance flexibility with financial security
More Advisor News

Annuity News

  • ‘It’s really shocking:’ Regulators scrutinize assets backing annuity sellers
  • Jackson Launches Direct-to-Consumer Annuity Offering
  • Global Atlantic launches ForeIncome Flex
  • Athene CEO criticizes offshore reinsurance, risk-taking by competitors
  • DOL, trade groups, state AGs file briefs supporting Alcoa in PRT lawsuit
More Annuity News

Health/Employee Benefits News

  • Medicaid work rules don’t apply to Native Americans. They could still lose coverage.
  • Oscar Highlights Tailored New Health Products in Florida for 2027 Open Enrollment
  • Oscar Highlights Tailored New Health Products in Texas for 2027 Open Enrollment
  • States get until July to cut Medicaid coverage over work requirement
  • CRUSH Rule could crush health insurance agents, industry group says
More Health/Employee Benefits News

Life Insurance News

  • Best’s Commentary: Shanghai Cross-Border Investment Pilot Unlocks Overseas Growth Potential of China Non-Life Companies
  • Military Briefs: November 19-25
  • California’s new solvency rules: What should life insurance advisors watch?
  • Navigating delayed death certificates: A guide for life insurance advisors
  • Jackson Launches Direct-to-Consumer Annuity Offering
More Life Insurance News

NEWS INSIDE

  • Companies
  • Earnings
  • Economic News
  • INN Magazine
  • Insurtech News
  • Newswires Feed
  • Regulation News
  • Washington Wire
  • Videos

FEATURED OFFERS

Press Releases

  • OpenRoad Insurance Data Shows 40% of Collector Vehicles Are Model Year 1980 or Newer
  • Insurvoice Lets Independent Insurance Agency Owners Analyze Every Customer Call in ChatGPT or Claude
  • Spectrum Weather & Specialty Insurance Celebrates 15 Years and Welcomes the Next Generation
  • Royal Neighbors of America® Increases Service Capacity
  • Benefits Studio Launches to Fill the Missing Middle of Benefits Navigation at $49/mo
More Press Releases > Add Your Press Release >

How to Write For InsuranceNewsNet

Find out how you can submit content for publishing on our website.
View Guidelines

Topics

  • Advisor News
  • Annuity Index
  • Annuity News
  • Companies
  • Earnings
  • Fiduciary
  • From the Field: Expert Insights
  • Health/Employee Benefits
  • Insurance & Financial Fraud
  • INN Magazine
  • Insiders Only
  • Life Insurance News
  • Newswires
  • Property and Casualty
  • Regulation News
  • Sponsored Articles
  • Washington Wire
  • Videos
  • ———
  • About
  • Meet our Editorial Staff
  • Advertise
  • Contact
  • Newsletters

Top Sections

  • AdvisorNews
  • Annuity News
  • Health/Employee Benefits News
  • InsuranceNewsNet Magazine
  • Life Insurance News
  • Property and Casualty News
  • Washington Wire

Our Company

  • About
  • Advertise
  • Contact
  • Meet our Editorial Staff
  • Magazine Subscription
  • Write for INN

Sign up for our FREE e-Newsletter!

Get breaking news, exclusive stories, and money- making insights straight into your inbox.

select Newsletter Options
Facebook Linkedin Twitter
© 2026 InsuranceNewsNet.com, Inc. All rights reserved.
  • Terms & Conditions
  • Privacy Policy
  • InsuranceNewsNet Magazine

Sign in with your Insider Pro Account

Not registered? Become an Insider Pro.